Rifampicin (Rifamycin AMP) is a broad-spectrum antibiotic. Rifampicin has a strong antibacterial effect against Mycobacterium tuberculosis and is also effective against gram-positive and gram-negative bacteria and viruses.

METHODS: PC12 cells were treated with Rifampicin (25-100 µM) for 3-24 h. The expression levels of target proteins were detected by Western Blot.
RESULTS: At 6 h of incubation, Rifampicin induced a significant increase in GRP78 protein expression in PC12 cells. Prolonged incubation with Rifampicin further enhanced the induction of GRP78 up to 24 h. PC12 cells showed a dose-dependent induction of GRP78 when incubated with Rifampicin at concentrations in the 25-100 µM range. [1]
METHODS: Human colon cancer cells LS180 were treated with Rifampicin (10 µM) for 24-144 h. Gene levels were measured by RT-PCR.
RESULTS: The total expression of NR1I2 mRNA was reduced by 40% after 24 h of Rifampicin treatment, and the expression of PXR.3 mRNA was reduced by 45% after 24 h of Rifampicin treatment. [2]

Rifampicin (200, 400 mg/kg) can induce fatty liver at high concentrations [4]. Rifampicin (30 mg/kg, i.p.) treatment of S464P biofilms in vivo causes a slight decline in bioluminescence from these catheters compared with the parental signal, but it does not affect bioluminescence in mice infected with mutant H481Y [5].